ACKNOWLEDGEMENT

This activity is supported by an educational grant from Bristol Myers Squibb and Janssen Biotech, Inc.

RELEASE/EXPIRATION DATES

March 22^nd 2024. Expires March 22^nd 2025

TARGET AUDIENCE

The intended audience for this program is hematology-oncologists, myeloma specialists, hematologists, heme-onc pharmacists, and nurses.

STATEMENT OF NEED/PROGRAM OVERVIEW

Standard-of-care frontline therapies do not have durable efficacy, with most patients eventually relapsing. In this setting, the number of therapeutic options for relapsed/refractory MM (RRMM) has expanded leading to improved survival outcomes for people with MM.

Join an expert panel of hematologists/oncologists to discuss how clinicians can apply evidence-based guidelines to care, select the right therapy with the greatest clinical benefit for each patient, and differentiate among potentially practice-changing therapies. Panelists will also discuss how clinicians can remain familiar with the adverse events associated with newer therapy and key aspects of monitoring patients post therapy.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Evaluate challenges to providing guideline-concordant care beyond the first-line
• Review new and emerging data and potentially practice-changing clinical trials in the relapsed-refractory setting
• Explain how to facilitate better alignment with patients/caregivers on goals of therapy

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.  
All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Monique Hartley-Brown, MD, MMSc Attending Physician, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Associate Physician Brigham & Women's Hospital Department of Medical Oncology Member of Faculty, Harvard Medical School	Consulting Fee (e.g., Advisory Board): AbbVie, Bristol Myers Squibb/Celgene, GSK, Janssen, Karyopharm Therapeutics, Sanofi Speaker's Bureau: AbbVie, Bristol Myers Squibb/Celgene, GSK, Janssen, Karyopharm, Sanofi
Melissa Alsina, MD Professor of Medicine in the Blood and Marrow Transplant Program at Moffitt Cancer Center Head of the Multiple Myeloma Transplant Program Moffit Cancer Center	Consulting Fee (e.g., Advisory Board): Janssen, BMS, Genzyme, Sanofi Contracted Research (Principal Investigators must provide information, even if received by the institution): BMS, Janssen

The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, OMedLive, at 877-394-1306 or at Support@OMedLive.com.